Compare ESCA & WHWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESCA | WHWK |
|---|---|---|
| Founded | 1922 | 2007 |
| Country | United States | United States |
| Employees | N/A | 23 |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 257.2M | 233.4M |
| IPO Year | 1995 | N/A |
| Metric | ESCA | WHWK |
|---|---|---|
| Price | $18.82 | $4.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 31.2K | ★ 573.3K |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.50% | N/A |
| EPS Growth | ★ 6.45 | N/A |
| EPS | ★ 0.32 | N/A |
| Revenue | ★ $180,541,000.00 | N/A |
| Revenue This Year | $4.15 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $59.56 | ★ N/A |
| Revenue Growth | ★ 2.71 | N/A |
| 52 Week Low | $11.41 | $1.57 |
| 52 Week High | $21.32 | $5.50 |
| Indicator | ESCA | WHWK |
|---|---|---|
| Relative Strength Index (RSI) | 53.32 | 43.93 |
| Support Level | $17.42 | $3.85 |
| Resistance Level | $18.91 | $4.38 |
| Average True Range (ATR) | 0.78 | 0.34 |
| MACD | 0.05 | -0.02 |
| Stochastic Oscillator | 68.00 | 5.47 |
Escalade Inc manufactures and distributes sporting goods for a varied range of activities. These sports include archery, table tennis, basketball goals, trampoline, play systems, fitness, game tables like hockey and soccer, billiards, darting, and other outdoor games. These products are sold under the brand names like Goalrilla, Goalsetter, Woodplay, Silverback, Nodor, Rage, Child Life, among others. The geographic segments in which the company operates are the United States, Canada, Australia, and Other regions.
Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.